These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 15385105)
1. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. Brustmann H Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Brustmann H Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054 [TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Brustmann H; Naudé S Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975 [TBL] [Abstract][Full Text] [Related]
4. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Brustmann H Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981 [TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Brustmann H Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315 [TBL] [Abstract][Full Text] [Related]
6. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer. Brustmann H Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250 [TBL] [Abstract][Full Text] [Related]
7. Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study. Brustmann H Gynecol Oncol; 2004 Jan; 92(1):268-76. PubMed ID: 14751170 [TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immunostaining. Garzetti GG; Ciavattini A; Lucarini G; Pugnaloni A; De Nictolis M; Amati S; Romanini C; Biagini G Gynecol Oncol; 1999 Jun; 73(3):396-401. PubMed ID: 10366466 [TBL] [Abstract][Full Text] [Related]
9. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma. Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598 [TBL] [Abstract][Full Text] [Related]
10. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection. Engels K; du Bois A; Harter P; Fisseler-Eckhoff A; Kommoss F; Stauber R; Kaufmann M; Nekljudova V; Loibl S J Clin Pathol; 2009 May; 62(5):448-54. PubMed ID: 19126566 [TBL] [Abstract][Full Text] [Related]
11. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
12. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma]. Sun LX; Wu Y; Han HQ; Wang QH Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438 [TBL] [Abstract][Full Text] [Related]
13. Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study. Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S J Med Assoc Thai; 2009 Mar; 92(3):308-14. PubMed ID: 19301721 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788 [TBL] [Abstract][Full Text] [Related]
15. [Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma]. Shi HR; Song WJ; Chen ZM; Wu QH Ai Zheng; 2005 Sep; 24(9):1127-31. PubMed ID: 16159439 [TBL] [Abstract][Full Text] [Related]
16. [Expressions of VEGF/VEGFRs and activation of STATs in ovarian carcinoma]. Chen BY; Ye DF; Xie X; Chen HZ; Lü WG Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):33-7. PubMed ID: 15771796 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance of DEK overexpression in serous ovarian tumors. Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407 [TBL] [Abstract][Full Text] [Related]
19. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Chen H; Ye D; Xie X; Chen B; Lu W Gynecol Oncol; 2004 Sep; 94(3):630-5. PubMed ID: 15350351 [TBL] [Abstract][Full Text] [Related]
20. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]